Sign In
Buy CBAY
$32.48
+0 (+0%)
At Close: Apr 11, 2024
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
08:30am, Monday, 12'th Feb 2024
FOSTER CITY, Calif. & NEWARK, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will
CymaBay Therapeutics to Participate in Upcoming Investment Conferences
08:00am, Wednesday, 31'st Jan 2024
NEWARK, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic disea
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:28pm, Tuesday, 16'th Jan 2024
NEWARK, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic dise
-- First clinical trial in PBC to show coordinate reductions of IL-31, bile acids and pruritus -- NEWARK, Calif. , Jan. 3, 2024 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmace
CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024
08:00am, Tuesday, 02'nd Jan 2024
NEWARK, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic disea
CymaBay Therapeutics to Present at Upcoming Investment Conferences
08:00am, Monday, 06'th Nov 2023
NEWARK, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic disea
CymaBay Therapeutics to Report Third Quarter of 2023 Financial Results on Tuesday, November 7, 2023
04:05pm, Tuesday, 31'st Oct 2023
NEWARK, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic disea
CymaBay Therapeutics Inc. (CBAY) is on the Move, Here's Why the Trend Could be Sustainable
10:34am, Wednesday, 25'th Oct 2023
CymaBay Therapeutics Inc. (CBAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Why CymaBay Therapeutics Stock Rocketed Nearly 8% Higher Today
06:16pm, Monday, 23'rd Oct 2023
The leading drug candidate in the biotech's pipeline scored another win. Seladelpar's existing Breakthrough Therapy Designation was expanded by the FDA.
CymaBay Presents Results on the Potential of Seladelpar in Treatment of Patients with Primary Biliary Cholangitis at ACG 2023
04:05pm, Monday, 23'rd Oct 2023
Cholestatic pruritus expert leads plenary discussion of correlated decreases in serum IL-31 levels and pruritus among patients with PBC treated with seladelpar
7 ‘Strong Buy' Biotech Stocks to Rejuvenate Your Portfolio
09:24pm, Wednesday, 27'th Sep 2023
While the health innovation space presents wild risks, you could potentially swing the odds in your favor with strong buy biotech stocks. Specifically, these ideas represent publicly traded biotechnol
Why CymaBay Therapeutics Stock Is Sinking This Week
04:39pm, Thursday, 21'st Sep 2023
CymaBay Therapeutics stock is continuing a slide that began last week. The pullback came on the heels of the biotech's dilution-causing stock and warrant offering.
CymaBay Therapeutics to Present at the Cantor Global Healthcare Conference
08:00am, Friday, 15'th Sep 2023
NEWARK, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic dise
Why CymaBay Therapeutics Stock Triumphed Again on Tuesday
05:37pm, Tuesday, 12'th Sep 2023
The biotech upsized its planned share issue. It's now seeking to raise gross proceeds of $225 million; previously, it was aiming for $150 million.
Why CymaBay Therapeutics Stock Popped Again Today
06:31pm, Monday, 11'th Sep 2023
The biotech is going to the well for more capital. It is seeking to raise $150 million in a share-and-warrant flotation.
